We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Graybug (GRAY) to Review Strategic Alternatives, Stock Up
Read MoreHide Full Article
Graybug Vision, Inc. announced that its board of directors is willing to conduct a comprehensive review of strategic options and alternatives focused on maximizing shareholders’ value of the company.
As a part of this strategic review, Graybug is considering a potential sale of the company apart from evaluating other alternatives like an acquisition, merger, divestiture of assets, and private placement of equity securities, among others.
Shares of Graybug were up 35.4% on Tuesday following the announcement of the news. The stock has plunged 39.9% so far this year compared with the industry’s decline of 21.7%.
Image Source: Zacks Investment Research
The primary goal of the above-mentioned strategic review is to maximize shareholders’ value. The company is also looking to maximize its cash resource with several cost-containment measures.
Graybug had cash, cash equivalents, and short-term investments worth $55.3 million as of Mar 31, 2022.
Graybug is engaged in developing transformative medicines for ocular diseases. The company has a diversified portfolio of pipeline candidates that are being developed to treat vision-threatening diseases.
Graybug’s lead drug candidate, GB-102, is being developed as an intravitreal injection in early-stage studies for the treatment of wet age-related macular degeneration. The candidate is a microparticle formulation of a pan-VEGF inhibitor, Sutent (sunitinib). Also, GB-102 has the potential to benefit patients with diabetic retinopathy.
The company also boasts of a pipeline of novel gene therapies that are being developed to treat rare vision-threatening corneal and retinal diseases.
Strategic reviews and restructuring are often considered by companies as cost-cutting initiatives. However, it remains to be seen how this review of strategic alternatives helps the board of Graybug to maximize their shareholders value while leveraging its diversified pipeline.
The Zacks Consensus Estimate for Leap Therapeutics’ loss per share has narrowed 11.1% for 2022 and 5.9% for 2023 in the past 60 days.
Earnings of Leap Therapeutics have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion. LPTX delivered an earnings surprise of 1.92%, on average.
Aeglea BioTherapeutics’ loss per share estimates narrowed 19.4% for 2022 and 37.5% for 2023 in the past 60 days.
Earnings of Aeglea BioTherapeutics have surpassed estimates in two of the trailing four quarters and missed the same on the other two occasions. AGLE delivered an earnings surprise of 9.47%, on average.
Precision BioSciences’ loss per share estimates narrowed 26.2% for 2022 and 42.6% for 2023 in the past 60 days.
Earnings of Precision BioSciences have surpassed estimates in each of the trailing four quarters. DTIL delivered an earnings surprise of 76.15%, on average.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Graybug (GRAY) to Review Strategic Alternatives, Stock Up
Graybug Vision, Inc. announced that its board of directors is willing to conduct a comprehensive review of strategic options and alternatives focused on maximizing shareholders’ value of the company.
As a part of this strategic review, Graybug is considering a potential sale of the company apart from evaluating other alternatives like an acquisition, merger, divestiture of assets, and private placement of equity securities, among others.
Shares of Graybug were up 35.4% on Tuesday following the announcement of the news. The stock has plunged 39.9% so far this year compared with the industry’s decline of 21.7%.
Image Source: Zacks Investment Research
The primary goal of the above-mentioned strategic review is to maximize shareholders’ value. The company is also looking to maximize its cash resource with several cost-containment measures.
Graybug had cash, cash equivalents, and short-term investments worth $55.3 million as of Mar 31, 2022.
Graybug is engaged in developing transformative medicines for ocular diseases. The company has a diversified portfolio of pipeline candidates that are being developed to treat vision-threatening diseases.
Graybug’s lead drug candidate, GB-102, is being developed as an intravitreal injection in early-stage studies for the treatment of wet age-related macular degeneration. The candidate is a microparticle formulation of a pan-VEGF inhibitor, Sutent (sunitinib). Also, GB-102 has the potential to benefit patients with diabetic retinopathy.
The company also boasts of a pipeline of novel gene therapies that are being developed to treat rare vision-threatening corneal and retinal diseases.
Strategic reviews and restructuring are often considered by companies as cost-cutting initiatives. However, it remains to be seen how this review of strategic alternatives helps the board of Graybug to maximize their shareholders value while leveraging its diversified pipeline.
Zacks Rank & Stocks to Consider
Graybug currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the biotech sector are Leap Therapeutics, Inc. (LPTX - Free Report) , Aeglea BioTherapeutics, Inc. and Precision BioSciences, Inc. (DTIL - Free Report) , all carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for Leap Therapeutics’ loss per share has narrowed 11.1% for 2022 and 5.9% for 2023 in the past 60 days.
Earnings of Leap Therapeutics have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion. LPTX delivered an earnings surprise of 1.92%, on average.
Aeglea BioTherapeutics’ loss per share estimates narrowed 19.4% for 2022 and 37.5% for 2023 in the past 60 days.
Earnings of Aeglea BioTherapeutics have surpassed estimates in two of the trailing four quarters and missed the same on the other two occasions. AGLE delivered an earnings surprise of 9.47%, on average.
Precision BioSciences’ loss per share estimates narrowed 26.2% for 2022 and 42.6% for 2023 in the past 60 days.
Earnings of Precision BioSciences have surpassed estimates in each of the trailing four quarters. DTIL delivered an earnings surprise of 76.15%, on average.